Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 75 Publications

13 Customer Reviews

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Phase 3.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
Tankyrase-1 [1]
(Cell-free assay)
1 nM 5 nM 1.5 μM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\NVoc1KGR? NE\Rcm5KSzVyPUWuO|A2KCEQvF2g MX2xPFU2QTZzMx?=
KP6.3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUK0JIQ> NFPlXm1KSzVyPUGwMlQzQCEQvF2g NVLwV5o4OTh3NUm2NVM>
KP7.7 M2C4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWm0JIQ> MV7JR|UxRTV5IH7NJC=> M2DhRlE5PTV7NkGz
KB2P3.4 NFLucFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS5e|g{PCCm M4LidGlEPTB;MUK0JG0h NYDxZXE4OTh3NUm2NVM>
KB2P1.21 MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLHOEBl NHjscVRKSzVyPUi5NFchdk1i Mo[1NVg2PTl4MUO=
U373-MG M3\tcmN6fG:2b4jpZ{BCe3OjeR?= NWTmTGxkOSEQvF2g NIX5WJEzPCCq MYTJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 NVfWemlVOTh7NUS3NVI>
T98G MX7DfZRwfG:6aXOgRZN{[Xl? M1z0OlEh|ryPIB?= NXv1WmlFOjRiaB?= NF3YemtKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 NI\HeIkyQDl3NEexNi=>
U87-MG NHf4OpNEgXSxdH;4bYMhSXO|YYm= M2LaZlEh|ryPIB?= NXXQepNwOjRiaB?= MkDlTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? NWjpfphiOTh7NUS3NVI>
UVW M2HFPGN6fG:2b4jpZ{BCe3OjeR?= MlHLOVAxKG6P MXSyOEBp NXXYZ2xWUW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= Ml7XNVg6PTR5MUK=
HeLa NFX3boNHfW6ldHnvckBCe3OjeR?= NVLX[2F3PTByIH7N Ml3ROEBp NUK1[ot[S2G3c3XzJIEhdW:mZYP0JIRmdGG7IHnuJJJmcm:rbnnu[{Bw\iC{YXTpZZRqd25vaX7keYNm\CCGTlGgZpJm[Wu| MX:xPFk2PDdzMh?=
HeLa NHXCPGpHfW6ldHnvckBCe3OjeR?= NH23eIcyKM7:TTC= MVqyOEBp NVfPN5lpTW6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhWy2yaHHz[UBienKnc4S= NIPDSXoyQDl3NEexNi=>
T98G NVPZVlFoTnWwY4Tpc44hSXO|YYm= NWG5U3JVOSEQvF2g NHjJeIszPCCq MXnFcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDTMZBp[XOnIHHydoV{fA>? M1Wwe|E5QTV2N{Gy
L3 NFPSO4NEgXSxdH;4bYMhSXO|YYm= NHrjSo82KM7:TTC= M2n4Ulk3KGh? MkjLSG1UVw>? MUDTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy= NUPjS5NmOjBzMkS0OVk>
Granta-519 M1yzSGN6fG:2b4jpZ{BCe3OjeR?= MVS1JO69VSB? M3L4Olk3KGh? MVvEUXNQ M1LRT3NtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? NGWwXlMzODF{NES1PS=>
BT Mnf1R5l1d3SxeHnjJGF{e2G7 NFjwcW82KM7:TTC= NIC1bpY6PiCq M4jKT2ROW09? MXTTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt M3rD[VIxOTJ2NEW5
UPN2 MlW4R5l1d3SxeHnjJGF{e2G7 NYrKc2lpPSEQvF2g M2PFW|k3KGh? MYPEUXNQ NHzr[2VUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu M3:1UlIxOTJ2NEW5
HBL-2 MYfDfZRwfG:6aXOgRZN{[Xl? M3vicVUh|ryPIB?= NWK2NpFIQTZiaB?= NHTlbppFVVOR NFqwTGdUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu NX3KUYxCOjBzMkS0OVk>
JVM-2 M3jJW2N6fG:2b4jpZ{BCe3OjeR?= NYXtUmZGPSEQvF2g NYfEWmw6QTZiaB?= MoD6SG1UVw>? NGHRPYZUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu NGLI[XMzODF{NES1PS=>
Z138 NXXvTol1S3m2b4TvfIlkKEG|c3H5 MYq1JO69VSB? NELkXJk6PiCq MXHEUXNQ M{HQXnNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? Mo[5NlAyOjR2NUm=
RWPE M4LOXWlvfmG|aY\lJGF{e2G7 MmHoNlUh|ryP MYq0PEBp MV\EUXNQ NF6x[XhUcWewaX\pZ4FvfGy7IILl[JVk\XNiRWLHMYRzcX[nbjDj[YxtKGmwdnHzbY9v M1zOb|IyPTd3OE[1
VCaP NUf6d5NZUW64YYPpeoUhSXO|YYm= MX[yOUDPxE1? MXS0PEBp NH7PfIJFVVOR NX;SOm9PW2mpbnnmbYNidnSueTDy[YR2[2W|IFXSS{1lemm4ZX6gZ4VtdCCrbo\hd4lwdg>? MoezNlE2PzV6NkW=
Mouse H2AX−/− ES Cells NECxcG9EgXSxdH;4bYMhSXO|YYm= M4nFcVIvPSEQvF2= MljUNlAhcA>? M3LjcnNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> MoPUNlM{PTV2OEm=
Mouse ATM−/− ES Cells NYjNPZFIS3m2b4TvfIlkKEG|c3H5 NUS4elRFOi53IN88US=> NXnZUndXOjBiaB?= NXzIcJVIW2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKHO3co\peoFt M{\TZ|I{OzV3NEi5
H1650 M2jjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDVU5MzOCEQvF2= MV:xOFQhcA>? M4P5fWlEPTB;MUWuOFch|ryP NFOybXczOzJ|OUiwPS=>
H1650PTEN+ M3zKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWeyNEDPxE1? MmjONVQ1KGh? NWq0PWJMUUN3ME21NE45OyEQvF2= M17XTFI{OjN7OEC5
PC-9 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCyNEDPxE1? MojqNVQ1KGh? MW\JR|UxRTVwOEig{txO NITmd2ozOzJ|OUiwPS=>
PC-9PTEN− MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG5eGYzOCEQvF2= MofFNVQ1KGh? NWTZfHVPUUN3ME22MlUzKM7:TR?= NY\GWWtQOjN{M{m4NFk>
MDA-MB-231 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV30XpN[PSCmYYm= MlnpTWM2OD14Lkmg{txO MXOyN|c3ODR7Nh?=
MDA-MB-468 M{jVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rE[VUh\GG7 NWfxfG9RUUN3ME21MlAh|ryP Mn7VNlM4PjB2OU[=
BT20 NF3TZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;SclM2KGSjeR?= MmnETWM2OD15Lkeg{txO M4nXVlI{PzZyNEm2
HCC1143 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlflOUBl[Xl? MXrJR|UxRTFzLkGg{txO NYLrSnM6OjN5NkC0PVY>
HCC1937 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fsPVUh\GG7 MmC1TWM2OD1zMj62JO69VQ>? NEK3UY8zOzd4MES5Oi=>
Hs578t NIHIPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLVOUBl[Xl? MoTmTWM2OD13Lk[g{txO MYCyN|c3ODR7Nh?=
Hs578t(si) M{XFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYS1JIRigQ>? NXTZbYw6UUN3ME23MlUh|ryP NEnQeIEzOzd4MES5Oi=>
BT474 NEHD[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrk[XA2KGSjeR?= NHPLOW9KSzVyPUG5Mlgh|ryP NVHQR4F5OjN5NkC0PVY>
JIMT1 M{\Mfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLQOUBl[Xl? M1nlRWlEPTB;Nz63JO69VQ>? NX3NTndyOjN5NkC0PVY>
SKBR3 MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYK1JIRigQ>? NHXD[VdKSzVyPUGxMlEh|ryP MoDyNlM4PjB2OU[=
SUM159 NIrJZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPJe5E1PSCmYYm= NHvZPIxKSzVyPUSuNkDPxE1? NHK1NHUzOzd4MES5Oi=>
CAMA1 NYXzO4xjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPJTm82KGSjeR?= NWfScpVoUUN3ME2xOU45KM7:TR?= MnrhNlM4PjB2OU[=
MCF7 NXO4VmxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS2N2VEPSCmYYm= M3TFVmlEPTB;NT64JO69VQ>? Mm\0NlM4PjB2OU[=
T47D NXHCO5kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{OwZ|Uh\GG7 M2jU[mlEPTB;OT62JO69VQ>? MYOyN|c3ODR7Nh?=
HCT116 Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T0bVExOCEQvF2= M3nJdVQ5KGh? MoCxSG1UVw>? MVLJR|UxRTJwNTFOwG0h M4npU|I1PTd5OUSx
SW1116 NFHjXGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHjSoEyODBizszN MWW0PEBp M4nzR2ROW09? MVrJR|UxRTFyMDFOwG0> MUiyOFU4Pzl2MR?=
HT29 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2flTFExOCEQvF2= NEDnR5c1QCCq MmnpSG1UVw>? NULyXHAyUUN3ME2xOE44KM7:TR?= M4jCS|I1PTd5OUSx
LoVo M4nNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILSfFcyODBizszN M2PKbVQ5KGh? MlvHSG1UVw>? MkTCTWM2OD1zMz60JO69VQ>? MViyOFU4Pzl2MR?=
HCT-15 NEjDfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGriWVUyODBizszN MV[0PEBp MmDhSG1UVw>? MVPJR|UxRTFyIN88US=> NFX1UJkzPDV5N{m0NS=>
SW48 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfSOGkyOTByIN88US=> MnHxOFghcA>? M1LBfGROW09? MUPJR|UxRTlwNTFOwG0> Mn3VNlQ2Pzd7NEG=
C-1 Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHhNVAxKM7:TR?= MnHoOFghcA>? NEHoN5FFVVOR MmPVTWM2OD15Lk[g{txO MVeyOFU4Pzl2MR?=
RKO MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jS[VExOCEQvF2= NXHaO28xPDhiaB?= MkS4SG1UVw>? NEHZO|BKSzVyPUWuPUDPxE1? MUCyOFU4Pzl2MR?=
HCT116 NVjWc25tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFToPVkyODBizszN NV;DcI1yPDhiaB?= NWLPcoNNTE2VTx?= MmezVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? MVSyOFU4Pzl2MR?=
SW1116 NXLWN21kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG0NVAxKM7:TR?= NGDYPJY1QCCq M1zFe2ROW09? NH\3fVRRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NF;VOZozPDV5N{m0NS=>
HT29 M4nifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSxNFAh|ryP NXfYcnIzPDhiaB?= MV;EUXNQ NVXuTVdrWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MmL0NlQ2Pzd7NEG=
LoVo NFPWboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PUdVExOCEQvF2= NITz[5A1QCCq Mm\YSG1UVw>? MXjQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh Ml3PNlQ2Pzd7NEG=
SW48 MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrDdlUyODBizszN M2nRNVQ5KGh? MkSySG1UVw>? MoLqVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? NV;m[oNmOjR3N{e5OFE>
C-1 M3nDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fUWVExOCEQvF2= NYKyeXdGPDhiaB?= NWLaNpNqTE2VTx?= MYrQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh MVqyOFU4Pzl2MR?=
RKO NVy4TGltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3yNVAxKM7:TR?= M3f5eFQ5KGh? NX\GTI5vTE2VTx?= Mn7QVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? NIDIcpUzPDV5N{m0NS=>
HCT116 Mo\ZSpVv[3Srb36gRZN{[Xl? M17abVExKG6P NFfuU28yOiCq MlrYSG1UVw>? NXfjcYZ7UW6lcnXhd4V{KESQQTDkc5VjdGVvc4TyZY5lKGK{ZXHrd{BqdmS3Y3XkJIJ6KFOQLUO4 NVzGcI1nOjR3N{e5OFE>
HT29 NXzEcGN1TnWwY4Tpc44hSXO|YYm= MoL4NVAhdk1? M4rSXFEzKGh? MlTBSG1UVw>? MkLFTY5kemWjc3XzJGRPSSCmb4XicIUue3S{YX7kJIJz\WGtczDpcoR2[2WmIHL5JHNPNTN6 NEXZOHkzPDV5N{m0NS=>
TE-6 NIjrSVlHfW6ldHnvckBCe3OjeR?= Mke0OUDPxE1i MVmxNkBp M4DqV2ROW09? M4TCXmlv\HWlZYOgS|IwVSCjcoLld5Q> M{e2cVI1OjF7MU[0
TE-6 MofOSpVv[3Srb36gRZN{[Xl? NFrHVY82KM7:TTC= NFTB[YozPCCq NW\BRWU3TE2VTx?= NXvZT|dpUW6lcnXhd4V{KGmwIHTveYJt\SC|dILhcoQh[nKnYXvzJEhFW0K|KR?= MWiyOFIyQTF4NB?=
Hep3B M1vjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LDXFQxKM7:TTC= NE\0Sm84OiCq NV3rfY5uTE2VTx?= NEjjTHJUgW6ncnfpd5Rq[2GubImgbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2m2aDDETG1GWQ>? M33rcFI2ODd{N{Wy
Huh7 MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjWXpkxPDBizszNJC=> NFrvNWI4OiCq M1f0NWROW09? NU\ucHp{W3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF? NV\m[YJ5OjVyN{K3OVI>
Hep3B NXnh[mxmTnWwY4Tpc44hSXO|YYm= MoHsOFAh|ryPIB?= Mn7RNlQhcA>? NVrzZnptTE2VTx?= NYn1d2pkUW6mdXPld{BTV1NicILv[JVkfGmxbjD3bZRpKESKTVXR MUOyOVA4Ojd3Mh?=
Huh7 MmDZSpVv[3Srb36gRZN{[Xl? NWjBbIx1PDBizszNJC=> MVOyOEBp NG[wTnJFVVOR MU\JcoR2[2W|IGLPV{Bxem:mdXP0bY9vKHerdHigSGhOTVF? NVrHN2JROjVyN{K3OVI>
Hep3B Mk[xSpVv[3Srb36gRZN{[Xl? NGjEbWI1OCEQvF2g NWL3OY83OjRiaB?= M1HLemROW09? NF;RS|RKdmS3Y3XzJINmdGxiYYX0c5Bp[We7IIfpeIghTEiPRWG= MnX6NlUxPzJ5NUK=
Huh7 M2PFXWZ2dmO2aX;uJGF{e2G7 M2\6RVQxKM7:TTC= M{DTS|I1KGh? NEXibI1FVVOR M2m0d2lv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?= M4nOZVI2ODd{N{Wy
SGC-7901 M33sSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;mNFMxyqEQvF2= NIr2UpM1QCCq MX;EUXNQ M13NWWJtd2OtIH;4ZYxqeGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NF\XdIIzPTd4N{C3Oi=>
COLO-800 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwNESxOlQh|ryP NHviR3VUSU6JRWK=
EoL-1- M37LOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MormTWM2OD1yLkW2OFQ3KM7:TR?= M2jj[XNCVkeHUh?=
NCI-H209 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwOUG1OVYh|ryP M3HCZ3NCVkeHUh?=
ES1 MkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDwTWM2OD1zLkGxOFA5KM7:TR?= MYnTRW5ITVJ?
NKM-1 NWT3O2RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr3cmRKSzVyPUGuNlU{PDdizszN M3O0eXNCVkeHUh?=
NTERA-S-cl-D1 MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LuO2lEPTB;MT6zN|M1OSEQvF2= M2DzfXNCVkeHUh?=
MHH-ES-1 Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrLTWM2OD1zLk[yNFY4KM7:TR?= MYjTRW5ITVJ?
ES8 M1;CTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\kNVhnUUN3ME2xMlczPDF2IN88US=> NHPCdJVUSU6JRWK=
NCI-H720 Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJwMkC2PVkh|ryP MX;TRW5ITVJ?
EW-3 NUjCbHdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXwTWM2OD1{LkK3OVM1KM7:TR?= M1LqTnNCVkeHUh?=
D-566MG M4W0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TvXGlEPTB;Mj60OFU3QCEQvF2= NXzZbpI4W0GQR1XS
697 M4e3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\aTWM2OD1{Lki0NVc{KM7:TR?= NYmwVlVEW0GQR1XS
ES5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PlXWlEPTB;Mj64PFE5QSEQvF2= NYi3WHlTW0GQR1XS
COLO-684 Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTNwNUG2PVYh|ryP NUP2N|ZOW0GQR1XS
ML-2 M4LpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TjeGlEPTB;Mz62NFA2QCEQvF2= NFS2eXpUSU6JRWK=
MC-IXC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2juZWlEPTB;Mz62N|M6OyEQvF2= NYTqS2pEW0GQR1XS
DB MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTNwNkW0OFgh|ryP NUP3bXQ5W0GQR1XS
HCC2218 M1HGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfEeItKSzVyPUOuO|MyODNizszN MkjUV2FPT0WU
NCI-H510A M3z1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTNwOEK3NlQh|ryP MVPTRW5ITVJ?
NCI-H526 NWDJSmpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PaPGlEPTB;Mz64Olk2QCEQvF2= NXjrU4VUW0GQR1XS
MV-4-11 NFHNSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXzTWM2OD12LkGzN|M1KM7:TR?= NHLocmdUSU6JRWK=
PA-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTVTWM2OD12LkK1Nlkh|ryP NY\lNGl{W0GQR1XS
EW-22 Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPBWIxKSzVyPUSuN|U5PiEQvF2= NV;OTYhWW0GQR1XS
KASUMI-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XqXmlEPTB;ND60NFExQSEQvF2= M3zKT3NCVkeHUh?=
LU-139 M3HzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL2R2ZKSzVyPUSuO|U5OjlizszN NFy2SolUSU6JRWK=
SBC-1 MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXWPYtKSzVyPUSuPFA6ODhizszN M{LHeHNCVkeHUh?=
H4 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD2TWM2OD12Lki5OFQ{KM7:TR?= MWLTRW5ITVJ?
EW-11 Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXPT3VVUUN3ME21MlA5ODd{IN88US=> M1vuVnNCVkeHUh?=
NBsusSR MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTVwMUKwOVUh|ryP NYjnSpltW0GQR1XS
RPMI-8226 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTVwMUWyOFQh|ryP MVLTRW5ITVJ?
DEL NF3RTXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPWTWM2OD13LkKwNFA3KM7:TR?= MlPlV2FPT0WU
ES4 M1LDSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfLTWM2OD13LkWxN|g6KM7:TR?= M1nZSHNCVkeHUh?=
GCT MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTVwNU[4OVYh|ryP NWO3TJN{W0GQR1XS
NCI-H1048 MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7sdIZKSzVyPUWuPVczPzNizszN MlTKV2FPT0WU
NCI-SNU-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTZwMEKyJO69VQ>? NFvsPHBUSU6JRWK=
ES7 NYPtT2VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[3TWM2OD14LkCzOVc4KM7:TR?= MXHTRW5ITVJ?
SW982 M4G1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTZwMEmxN|ch|ryP M1\PVXNCVkeHUh?=
L-363 NGL2WHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTZwM{O5O|Qh|ryP MmDYV2FPT0WU
HT-1080 NYi2S2I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vlVWlEPTB;Nj60PVY5OyEQvF2= NIH4XJFUSU6JRWK=
HAL-01 NI\NTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTuOox[UUN3ME22MlUyODlizszN M{L3NnNCVkeHUh?=
NB14 M3nld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPTTWM2OD14Lk[0NFM6KM7:TR?= M4\rVHNCVkeHUh?=
EW-13 M2iycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHGPYhKSzVyPU[uO|c1OjRizszN MYHTRW5ITVJ?
NY M1;MXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;oSWVMUUN3ME22Mlk1PjB3IN88US=> M3T0fXNCVkeHUh?=
NCI-SNU-5 M2LGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXSyRY57UUN3ME23MlExPDN|IN88US=> MXzTRW5ITVJ?
MS-1 M3jyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnUSVR4UUN3ME23MlE4PDl2IN88US=> NE\2NlZUSU6JRWK=
EW-16 NXz5PZFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\BT2lEPTB;Nz6zNVg3OSEQvF2= MULTRW5ITVJ?
LU-65 NGO5ZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7K[YFPUUN3ME23MlQ5PDF5IN88US=> NYfEXYdRW0GQR1XS
HGC-27 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTtUFNlUUN3ME23MlczOTd|IN88US=> Ml7VV2FPT0WU
CTB-1 M3nFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f5OGlEPTB;Nz63OlE4PSEQvF2= M1mwZnNCVkeHUh?=
5637 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzNTWM2OD15LkmyPFYh|ryP NVjDXolZW0GQR1XS
U251 NEfNd|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH72bpBKSzVyPUeuPVQxOTZizszN MX\TRW5ITVJ?
HOS M3jJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfYTWpKSzVyPUiuNlMxODdizszN NF3IOZdUSU6JRWK=
DOHH-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL0TWM2OD16LkKzOVgh|ryP MYfTRW5ITVJ?
EW-1 NF7YVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfxWoxHUUN3ME24MlMxODh6IN88US=> MmS0V2FPT0WU
BV-173 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLlR2FoUUN3ME24MlU2PTRizszN NHL0fHZUSU6JRWK=
8-MG-BA NVnzZ4E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjHbXJKSzVyPUiuOlg6QDhizszN M3TzeHNCVkeHUh?=
NB69 NWrYZ5BwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LVd2lEPTB;OD63NFkzOSEQvF2= M4\sc3NCVkeHUh?=
NCI-H69 NIjaOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXLd2lKUUN3ME25MlkxQTZzIN88US=> MWnTRW5ITVJ?
RS4-11 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrRTWM2OD1zMT6yNlA5KM7:TR?= NGnQWWhUSU6JRWK=
ONS-76 NULNdoxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFixXYtKSzVyPUGxMlI6PDdizszN MoPUV2FPT0WU
SF539 NWLrN5ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q0XmlEPTB;MUGuOFg5QSEQvF2= Mm\KV2FPT0WU
HuO-3N1 NWTQbI1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PpeWlEPTB;MUGuOVc6PiEQvF2= M13MW3NCVkeHUh?=
NCI-H1651 MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4GzN2lEPTB;MUKuN|EyPSEQvF2= MWTTRW5ITVJ?
KARPAS-45 MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF{LkO3OkDPxE1? NFnUU4RUSU6JRWK=
SK-NEP-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGGxem1KSzVyPUGyMlQ3ODlizszN MYHTRW5ITVJ?
LAMA-84 NFXvNpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXMW2E2UUN3ME2xN{4yODl3IN88US=> M3\ieXNCVkeHUh?=
NCI-H1155 M1q0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF31UJBKSzVyPUGzMlI5PTZizszN NUXvXmJXW0GQR1XS
CTV-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfZc3pKSzVyPUGzMlQ1PSEQvF2= MYjTRW5ITVJ?
QIMR-WIL M{nLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7YZnBKSzVyPUGzMlc5OTRizszN M1i4O3NCVkeHUh?=
H9 NH7kUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r3XGlEPTB;MUOuPFQ4PSEQvF2= NEXSWFlUSU6JRWK=
SK-MEL-1 M2POeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTF|LkmzOFch|ryP Mnn1V2FPT0WU
HD-MY-Z NX;Ub3pUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H0N2lEPTB;MUSuNFY{PyEQvF2= MVrTRW5ITVJ?
TI-73 MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\LXmtqUUN3ME2xOE4zOzV4IN88US=> NX\BXHk2W0GQR1XS
JVM-3 M4fuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK3TWM2OD1zNT61O|E3KM7:TR?= MWPTRW5ITVJ?
D-247MG MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO1SFlZUUN3ME2xOU42QTNizszN M1rKUHNCVkeHUh?=
VA-ES-BJ MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HYRmlEPTB;MUWuOlA6PyEQvF2= NH7CdJRUSU6JRWK=
NOS-1 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i0dmlEPTB;MUWuOlUzOiEQvF2= M{\KPHNCVkeHUh?=
MOLT-4 NIHxeGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy5d3k{UUN3ME2xOk44PTJizszN MkHkV2FPT0WU
Mo-T MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7ZVlBKSzVyPUG3MlA5PDlizszN NXTrd206W0GQR1XS
NCI-H1770 NYTQRo96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIT3V5lKSzVyPUG3MlE2PDNizszN M3\4OnNCVkeHUh?=
COLO-320-HSR M1mwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm5S3VKSzVyPUG3MlE5OjdizszN M{D0SnNCVkeHUh?=
TE-12 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK2PWsyUUN3ME2xO{44ODV2IN88US=> M33PcnNCVkeHUh?=
NCI-H82 M2CwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO5TWM2OD1zNz64O|I5KM7:TR?= Mn7VV2FPT0WU
NEC8 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF6LkGzNVYh|ryP MoLxV2FPT0WU
HSC-3 NYDVTodMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnBTWM2OD1zOD63OFE1KM7:TR?= M33JdHNCVkeHUh?=
NCI-H1092 NWL1fJR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzlNZB5UUN3ME2xPE44PTl3IN88US=> MULTRW5ITVJ?
NCI-H292 M4LIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i2PWlEPTB;MUmuNFQ5QSEQvF2= MXLTRW5ITVJ?
L-428 NF7TNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTvWVU2UUN3ME2xPU42PTlizszN NU\4b|h5W0GQR1XS
LU-134-A MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jkc2lEPTB;MUmuOVczKM7:TR?= NHf5eFdUSU6JRWK=
GI-ME-N NVPlbZo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF7LkW3OFch|ryP NInsVVdUSU6JRWK=
ALL-PO MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof5TWM2OD1zOT61PVczKM7:TR?= MlfvV2FPT0WU
D-283MED MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH2TWM2OD1zOT65NVUh|ryP NFPSUGFUSU6JRWK=
D-423MG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDnNmVKSzVyPUG5Mlk6PjdizszN MW\TRW5ITVJ?
CAKI-1 MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInuSVBKSzVyPUKwMlIzOTlizszN NXzlXJF[W0GQR1XS
ETK-1 NHLkOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX5TWM2OD1{MD6yOlE2KM7:TR?= MXPTRW5ITVJ?
G-402 NGXOUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGryS5hKSzVyPUKwMlU{OzRizszN MWHTRW5ITVJ?
HL-60 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvJTWM2OD1{MT6xOlE{KM7:TR?= Mn;ZV2FPT0WU
A2058 M3;xUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:2VHlKSzVyPUKxMlQ1PzdizszN NETuT3BUSU6JRWK=
CHP-212 NHTwbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJzLkmwOVEh|ryP NUTVN4kyW0GQR1XS
KY821 Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzITWM2OD1{MT65O|Uh|ryP M4PVVHNCVkeHUh?=
TYK-nu NV6wenVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjnb5FLUUN3ME2yNk4xPjVzIN88US=> NUP1W2tMW0GQR1XS
JVM-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPPUVJ5UUN3ME2yNk4zQTh|IN88US=> MWrTRW5ITVJ?
KU812 M4HUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S4cWlEPTB;MkKuO|MyOiEQvF2= NFzWRlRUSU6JRWK=
MKN28 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ{LkmwNVUh|ryP NWfYVGg4W0GQR1XS
ECC10 M2KyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzMTWM2OD1{Mz63OFEh|ryP NXjQc4dxW0GQR1XS
BHT-101 NEPObJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT6c2sxUUN3ME2yOE4xODB6IN88US=> MkXoV2FPT0WU
DU-4475 NETB[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7SW2JKSzVyPUK0MlM{OzdizszN M{flUnNCVkeHUh?=
769-P NXXVfYlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJ2Lki0OlYh|ryP NVjQRXR4W0GQR1XS
HEC-1 NXjDcYRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJ3LkS0OUDPxE1? NVHnfpk5W0GQR1XS
MOLT-13 MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ3LkWzN|Eh|ryP NGLYPZpUSU6JRWK=
8505C M4Gxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjmT4xKSzVyPUK2MlQ6PzdizszN M1LWeHNCVkeHUh?=
GB-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJ4LkexO|Yh|ryP MoK5V2FPT0WU
SF126 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJ4Lke2OFgh|ryP MXvTRW5ITVJ?
A4-Fuk MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLRTWM2OD1{Nz6xNlcyKM7:TR?= MXHTRW5ITVJ?
OVCAR-8 NHrObZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HqXmlEPTB;MkeuNVU{QSEQvF2= MXzTRW5ITVJ?
NCI-H1304 MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3NTWM2OD1{Nz61OEDPxE1? NIHzT2VUSU6JRWK=
GR-ST M{fr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJ6LkC0O{DPxE1? Mkn0V2FPT0WU
G-401 NGTFbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon5TWM2OD1{OD61NFk3KM7:TR?= NV\ub3piW0GQR1XS
LXF-289 NVn3[HY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPvTWM2OD1{OD61OlUyKM7:TR?= M3jv[HNCVkeHUh?=
DBTRG-05MG MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzxfnZKSzVyPUK4MlkzODRizszN M2HCVnNCVkeHUh?=
YKG-1 NEXFWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LzU2lEPTB;MkmuPFY5KM7:TR?= MYXTRW5ITVJ?
GAMG NUjCTHZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPrNnBiUUN3ME2yPU46QTNizszN MXTTRW5ITVJ?
HCT-116 NXXPdFI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPtblE{UUN3ME2zNE4xPTR6IN88US=> NXq3XZJpW0GQR1XS
S-117 NEHBWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWewSWY{UUN3ME2zNU4zOjV5IN88US=> M1vBbHNCVkeHUh?=
NCI-H1693 NUXzR4tWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPPTWM2OD1|Mz62OVQzKM7:TR?= NHnld3hUSU6JRWK=
A427 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTN|Lkm5O|Yh|ryP MkDmV2FPT0WU
HT-29 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGOzcFNKSzVyPUO0MlYxOzJizszN MULTRW5ITVJ?
P12-ICHIKAWA M4Lodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzJbFVWUUN3ME2zOE44PDlzIN88US=> M3PYfnNCVkeHUh?=
CAL-51 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrrTWM2OD1|NT6wO|A6KM7:TR?= MlXyV2FPT0WU
Ramos-2G6-4C10 MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK1flFKSzVyPUO1MlI1OjVizszN M3;zS3NCVkeHUh?=
SCH MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvITWM2OD1|Nj60NVc1KM7:TR?= MnrqV2FPT0WU
SK-MEL-24 NX3HdHlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojOTWM2OD1|Nj65NFQ1KM7:TR?= NYTzNWk{W0GQR1XS
SW1573 Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjqTWM2OD1|OD63NlE3KM7:TR?= NFrpVmxUSU6JRWK=
BALL-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTN7LkKxNlkh|ryP M2rEbXNCVkeHUh?=
BE-13 MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\UTGhKSzVyPUO5MlMzQSEQvF2= MYnTRW5ITVJ?
GI-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\lTWM2OD1|OT64OlQ4KM7:TR?= NXfpSlhLW0GQR1XS
GOTO NYXmOJZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDUdmhKSzVyPUO5MlkyOzlizszN MkeyV2FPT0WU
A673 MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzxOWpuUUN3ME20NU4xOzR|IN88US=> NVvQVGlCW0GQR1XS
KG-1 M3;kW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;BTWM2OD12Mz6zPVQh|ryP MVLTRW5ITVJ?
GP5d M1\0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\vTWM2OD12ND6wOlY3KM7:TR?= M2n1d3NCVkeHUh?=
MFM-223 NF3wN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfUeHpCUUN3ME20OE4yOjJ6IN88US=> MmTUV2FPT0WU
OAW-42 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfxZ4JlUUN3ME20OE4zPjR|IN88US=> NUjrfoNtW0GQR1XS
C8166 NIjZNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1e4fWlEPTB;NEWuNFgzOiEQvF2= MYTTRW5ITVJ?
LU-99A MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTGTWM2OD12Nj6xN|IzKM7:TR?= MnLXV2FPT0WU
NCI-H23 NVjaWJJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnvO|hKSzVyPUS2MlE4QDVizszN MlHJV2FPT0WU
HO-1-N-1 M4rTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TONWlEPTB;NEeuNFk6QCEQvF2= Mn\xV2FPT0WU
A3-KAW MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTR5LkGwNFch|ryP MkXTV2FPT0WU
CGTH-W-1 M{T5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi4[Y5KSzVyPUS3MlUxPjlizszN MnTXV2FPT0WU
DJM-1 MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDwcmdKSzVyPUS3MlU1OTNizszN MVfTRW5ITVJ?
A101D M2fxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnKfHhlUUN3ME20O{43OzV5IN88US=> MWnTRW5ITVJ?
BB30-HNC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\zXGRKSzVyPUS4MlMxPzJizszN NWPYXXlrW0GQR1XS
T98G M4XwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDMTWM2OD12OD60OlM{KM7:TR?= Ml3lV2FPT0WU
NCI-H1573 NE\jNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL3eGdKSzVyPUS5MlQ1PjJizszN MVrTRW5ITVJ?
MEG-01 M{jacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHwTWM2OD12OT63OFEyKM7:TR?= NHGxZmNUSU6JRWK=
WM-115 NXT3cnN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zkWGlEPTB;NEmuPVIzOiEQvF2= NWLsV49qW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay
+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research
+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL (197.94 mM) warming
Water 0.002 mg/mL (0.0 mM)
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02546661 Not yet recruiting Muscle Invasive Bladder Cancer AstraZeneca August 2016 Phase 1
NCT02822157 Not yet recruiting Ovarian Epithelial Cancer Universitaire Ziekenhuizen Leuven|AstraZeneca August 2016 Phase 2
NCT02810743 Not yet recruiting Breast Cancer The Netherlands Cancer Institute August 2016 Phase 3
NCT02489006 Not yet recruiting Ovarian Cancer|Fallopian Tube Cancer|Neoadjuvant Treatment|Debulking Surgical Procedures University Health Network, Toronto July 2016 Phase 2
NCT02392676 Withdrawn Platinum Sensitive Relapsed Ovarian Cancer AstraZeneca|Myriad Genetic Laboratories, Inc. July 2016 Phase 3
NCT02787642 Not yet recruiting Soft-tissue Sarcoma Institut Bergonié|National Cancer Institute, France June 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How long can the chemical compound be stable in DMEM at 4 ℃?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID